Acurx Pharmaceuticals and Coya Therapeutics Compared

A critical analysis of the two small-cap medical companies and their investment potential.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Coya Therapeutics (NASDAQ:COYA) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? This article compares the two companies based on factors like net margins, return on equity, revenue, earnings per share, valuation, analyst recommendations, institutional ownership, and stock volatility.

Why it matters

This analysis provides investors with a comprehensive comparison of Coya Therapeutics and Acurx Pharmaceuticals, two promising small-cap biotech companies, to help them make informed investment decisions. Understanding the relative strengths and weaknesses of these firms is crucial for investors looking to capitalize on potential growth opportunities in the medical sector.

The details

The analysis found that Acurx Pharmaceuticals has lower revenue but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio, indicating it is currently more affordable. However, analysts believe Acurx Pharmaceuticals has higher potential upside based on its consensus target price. Coya Therapeutics has stronger institutional ownership, while Acurx Pharmaceuticals has higher insider ownership. Coya Therapeutics also has lower stock price volatility compared to Acurx Pharmaceuticals.

  • The analysis was published on March 4, 2026.

The players

Coya Therapeutics

A clinical-stage biotechnology company developing therapeutic modalities to modulate the function of regulatory T cells.

Acurx Pharmaceuticals

A clinical-stage biopharmaceutical company developing antibiotics to treat bacterial infections, including its lead candidate ibezapolstat.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the key differences between Coya Therapeutics and Acurx Pharmaceuticals, providing investors with valuable insights to assess the investment potential of these two small-cap medical companies. While both firms show promise, the data suggests Acurx Pharmaceuticals may have higher upside potential based on analyst projections, though Coya Therapeutics appears more affordable and less volatile.